Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Clinical trial NCT03780517 · COMPLETED
Trial details
- NCT number
- NCT03780517
- Sponsor
- Boston Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-12
- Primary completion
- 2023-09-26
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.